Dipotassium glycyrrhizinate

C[C@]12[C@@](C(C=C3[C@]2(CC[C@]4(C)[C@@]3([H])C[C@](C(O[K])=O)(C)CC4)C)=O)([H])[C@@]5([C@@](C(C)([C@@H](O[C@]6([H])[C@@H]([C@H]([C@H](O)[C@@H](C(O)=O)O6)O)O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C(O[K])=O)CC5)C)([H])CC1)C

[1]Lee SH, et al. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Arch Dermatol Res. 2019 Mar;311 (2) :131-140.|[2]Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017 Nov;95:599-604. |[3]Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27 (5) :722-731.|[4]Xu Z, et al. Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib. Autophagy. 2022 May;18 (5) :1152-1173.|[5]Gao L, et al. Glycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in rats. Front Pharmacol. 2015 Oct 1;6:215.

BioRxiv. 2025 Feb 19.|Mediators Inflamm. 2025 Jul 11:2025:2395557.|3 Biotech. 2020 Aug;10 (8) :369.|ACS Chem Neurosci. 2020 Mar 18;11 (6) :979-993.|Adv Biol (Weinh) . 2025 Jun 4:e00761.|Adv Healthc Mater. 2024 Jan;13 (2) :e2301808.|Adv Sci (Weinh) . 2024 Aug 5:e2404408.|Aging (Albany NY) . 2019 Jul 7;11 (13) :4323-4337.|Behav Brain Res. 2025 May 24:115662.|Biochem Biophys Res Commun. 2021 Feb 12:540:22-28.|bioRxiv. 2025 Feb 19.|BMC Immunol. 2021 May 27;22 (1) :34.|Cell Commun Signal. 2023 May 1;21 (1) :86.|Cell Death Discov. 2024 Jan 17;10 (1) :34.|Cell Prolif. 2020 Jun;53 (6) :e12829.|Cell Prolif. 2024 Nov 20:e13774.|Cell Signal. 2024 Mar:115:111036.|Chem Eng J. 2025 May 1.|CNS Neurosci Ther. 2025 May;31 (5) :e70406.|Drug Des Devel Ther. 2025 Apr 2:19:2503-2517.|EMBO Rep. 2025 Nov 17.|Eur J Med Res. 2025 Oct 9;30 (1) :943.|Eur J Pharmacol. 2025 Oct 5:1004:177971.|Evid Based Complement Alternat Med. 2020 May 31;2020:8653783.|Fish Shellfish Immunol. 2024 Jan:144:109261.|Food Res Int. 2025 Sep 26;222:117620.|Front Cell Dev Biol. 2020 Aug 11;8:713.|Hepatol Commun. 2023 Dec 22;8 (1) :e0350.|Int Immunopharmacol. 2025 Feb 3:149:114192.|Int Immunopharmacol. 2025 Mar 26:150:114294.|J Cell Mol Med. 2025 Nov;29 (21) :e70944.|J Exp Clin Cancer Res. 2024 Apr 4;43 (1) :105.|J Funct Foods. 2021, 104584.|J Inflamm Res. 2025 May 25:18:6735-6748.|Mater Today Bio. 2025 Apr 17:32:101778.|Mol Neurobiol. 2025 May;62 (5) :6070-6087.|Nat Nanotechnol. 2025 May 19.|Neuropharmacology. 2025 Nov 15:279:110617.|Pharm Biol. 2020 Dec;58 (1) :898-904.|Pharmaceuticals (Basel) . 2022 Jan 31;15 (2) :179.|Phytomedicine. 2024 Dec:135:156059.|Phytomedicine. 2025 Jul:142:156713.|Phytomedicine. 2025 Sep:145:157081.|Planta Med. 2021 Jun;87 (7) :538-549.|Res Sq. 2025 Oct 28.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Apr 27.|Research Square Print. August 24th, 2022.|Rev Bras Farmacogn. 2023 Jun 28.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|Sci Rep. 2025 Nov 12;15 (1) :39708.|SSRN. 2025 Jan 15.|SSRN. 2025 Jul 8.|SSRN. 2025 Nov 20.|Toxicol In Vitro. 2025 Oct:108:106104.|World Neurosurg. 2022 Feb:158:e856-e864.|bioRxiv. 2025 Feb 19.|Redox Rep. 2025 Dec;30 (1) :2585221.